Drugs in the Pipeline

Phase 3 Study Update of Tivozanib for First-Line Advanced Renal Cell Carcinoma

May 17, 2012

AVEO and Astellas announced detailed data from TIVO-1 (Tivozanib Versus Sorafenib in 1st line Advanced Renal Cell Carcionma [RCC]).

Phase 2 Trial Update of Tivantinib for Hepatocellular Carcinoma

May 17, 2012

ArQule and Daiichi Sankyo announced Phase 2 trial data with tivantinib as a single agent investigational second-line treatment in hepatocellular carcinoma (HCC).

Phase 2 Study Update of Rilotumumab (AMG 102) for Gastric and Gastroesophageal Cancer

May 17, 2012

Amgen announced results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102) conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer.

Phase 2 Study Update of Blinatumomab (AMG 103) for Relapsed or Refractory Acute Lymphoblastic Leukemia

May 17, 2012

Amgen announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72% of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

Phase 3 Trial Update of NVA237 for COPD

May 17, 2012

Sosei Group Corporation confirmed the information released today by Novartis that results from the pivotal Phase 3 GLOW2 study demonstrated that once-daily 50mcg NVA237 (glycopyrronium bromide) was superior to placebo in improving lung function, symptom relief and quality of life, and reducing exacerbations over a one-year period in patients with chronic obstructive pulmonary disease (COPD).

Phase 3 Trial of Vedolizumab for Crohn's Disease

May 11, 2012

Takeda announced results from the GEMINI II Phase 3 trial evaluating vedolizumab in patients with moderately to severely active Crohn's disease who have failed at least one conventional therapy, including TNFα antagonists.

Phase 2 Trial Update of Adcetris for Relapsed Cutaneous T-Cell Lymphoma

May 10, 2012

Seattle Genetics announced interim results from an investigator-sponsored Phase 2 clinical trial of Adcetris (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL).

NDA Accepted for BG-12 for Multiple Sclerosis

May 10, 2012

Biogen Idec announced that the FDA has accepted for filing the company's New Drug Application (NDA) for BG-12 (dimethyl fumarate) for the treatment of multiple sclerosis (MS).

sNDA Submitted for Xarelto for Reduction of the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome

May 09, 2012

Janssen Research & Development announced that it has submitted a supplemental New Drug Application (sNDA) to the FDA seeking approval for the use of Xarelto (rivaroxaban) to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome (ACS).

Phase 3 Study of Aripiprazole Intramuscular Depot for the Maintenance Treatment of Schizophrenia

May 07, 2012

Otsuka and Lundbeck announced results from a Phase 3 clinical trial evaluating the efficacy, safety and tolerability of once-monthly aripiprazole intramuscular (IM) depot formulation for the maintenance treatment of adults with schizophrenia.